2.45Open2.45Pre Close0 Volume25 Open Interest7.50Strike Price0.00Turnover130.36%IV7.51%PremiumAug 16, 2024Expiry Date2.04Intrinsic Value100Multiplier24DDays to Expiry0.41Extrinsic Value100Contract SizeAmericanOptions Type-0.7763Delta0.1639Gamma2.45Leverage Ratio-0.0104Theta-0.0034Rho-1.90Eff Leverage0.0043Vega
Biomea Fusion Stock Discussion
The pause on clinical trials seems to be a result of the explosion of industry regulations in recent years. From 2022 through 2024, the FDA has implemented "additional steps" to clinical trials, including bringing in outside agencies to help with oversight.
Red tape and bureaucracy, not BEMA, caused this pause. All the research I've done shows the pause was premature and overly cautious.
No comment yet